Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$2.25 CAD
Change Today 0.00 / 0.00%
Volume 0.0
MPH On Other Exchanges
As of 3:59 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

medicure inc (MPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/28/14 - C$2.97
52 Week Low
01/30/15 - C$1.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDICURE INC (MPH)

Related News

No related news articles were found.

medicure inc (MPH) Related Businessweek News

No Related Businessweek News Found

medicure inc (MPH) Details

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapeutics in Canada, the United States, and Barbados. It primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome. The company is also developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications; and Transdermal AGGRASTAT, which is in a preclinical stage for acute cardiology. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.

Founded in 1997

medicure inc (MPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medicure inc (MPH) Key Developments

Medicure Inc. Reports Results from Operations for the Seven Months Ended December 31, 2014

Medicure Inc. reported results from operations for the seven months ended December 31, 2014. The company recorded net revenue of $5.3 million during the seven months ended December 31, 2014, an increase of 143% compared to $2.2 million for the comparable period in the previous year. Earnings before interest, taxes, depreciation and amortization (EBITDA)1 for the seven months ended December 31, 2014 was $1.1 million compared to a loss of $238,000 for the comparable period in the previous fiscal year. Net income for the seven months ended December 31, 2014 was $1.2 million, compared to a net loss of $960,000 for the comparable period in the previous year. The increase in net income is primarily a result of other, non-cash, income relating to the value of Medicure's ownership interest in Apicore Inc., acquired on July 3, 2014, net of costs associated with the transaction, as a result of services provided by Medicure in its lead role in structuring a majority interest purchase and financing of Apicore. The improvement compared to the same period of the prior year is also due to increased revenue from the sale of AGGRASTAT during the seven months ended December 31, 2014, partially offset by selling, general and administration expenses. Cash flows from operating activities for the seven months ended December 31, 2014 were $276,000 compared to cash used in operating activities of $106,000 for the seven months ended December 31, 2013.

Medicure Inc. Auditor Raises 'Going Concern' Doubt

Medicure Inc. filed its 20-F on Apr 14, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Medicure Inc. Provides Revenues Guidance for the Calendar Year Ended December 31, 2014

Medicure Inc. provided revenues guidance for the calendar year ended December 31, 2014. For the twelve months ended December 31, 2014, the company’s net revenue from the sale of AGGRASTAT finished product for the twelve months ended December 31, 2014 is expected to be $8.425 million compared to $3.225 million for the twelve months ended December 31, 2013, an increase of 161%. As the company enters the 2015 calendar and fiscal year, hospital demand for AGGRASTAT continues to increase significantly. The increase in revenue is primarily attributable to a continuing increase in the number of new hospital customers using AGGRASTAT.  The number of new customers reviewing and implementing AGGRASTAT has increased sharply as a result of FDA approval of the new dosing regimen for AGGRASTAT as announced on October 11, 2013. Additionally, favorable fluctuations in the U.S. dollar exchange rate contributed to the increase in revenue.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MPH:CN C$2.25 CAD 0.00

MPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MPH.
View Industry Companies

Industry Analysis


Industry Average

Valuation MPH Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICURE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at